Skip to content

ENDONOVO THERAPEUTICS, INC.

ENDV · OTCM

CIK 1528172fmd_1EWE4A38EC53VA28HRKN0E5Z55Manufacturing · Electromedical & Electrotherapeutic ApparatusTemplate: Standard

Coverage: Jan 01, 2010 to Sep 30, 2023, 50 periods

Latest annual · FY2022

Millions
Total revenues
0
Gross profit
0
Operating income
(3)
Net income
(18)

Latest quarter · Q3 FY2023

Millions
Total revenues
0
Gross profit
0
Operating income
(0)
Net income
(1)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2019 to FY2022
-24.1%
Revenue, 5 yearsFY2017 to FY2022
n/m
Net income, 5 yearsFY2017 to FY2022
n/m

ENDONOVO THERAPEUTICS, INC. (ENDV) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2022FY2021ChangeSource
Revenue$135,355$73,105+85.2%10-K 2023-04-17 · proof
Gross profit$125,365$58,120+115.7%10-K 2023-04-17 · proof
Operating income-$3.3 million-$2.2 million10-K 2023-04-17 · proof
Net income-$18.5 million-$3.1 million10-K 2023-04-17 · proof
Cash from operating activities-$678,838-$986,58410-K 2023-04-17 · proof
Total assets$1.3 million$2 million-36.2%10-K 2023-04-17 · proof
Total liabilities$33.5 million$17.8 million+88.2%10-K 2023-04-17 · proof
Cash and cash equivalents$98$85,936-99.9%10-K 2023-04-17 · proof
What was ENDONOVO THERAPEUTICS, INC. (ENDV)'s revenue in fiscal 2022?
ENDONOVO THERAPEUTICS, INC. (ENDV) reported revenue of $135,355 for fiscal 2022 (the year ended Dec 31, 2022), against $73,105 the year before (+85.2%). Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What was ENDONOVO THERAPEUTICS, INC. (ENDV)'s gross profit in fiscal 2022?
ENDONOVO THERAPEUTICS, INC. (ENDV) reported gross profit of $125,365 for fiscal 2022 (the year ended Dec 31, 2022), against $58,120 the year before (+115.7%). Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What was ENDONOVO THERAPEUTICS, INC. (ENDV)'s operating income in fiscal 2022?
ENDONOVO THERAPEUTICS, INC. (ENDV) reported operating income of -$3.3 million for fiscal 2022 (the year ended Dec 31, 2022), against -$2.2 million the year before. Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What was ENDONOVO THERAPEUTICS, INC. (ENDV)'s net income in fiscal 2022?
ENDONOVO THERAPEUTICS, INC. (ENDV) reported net income of -$18.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -$3.1 million the year before. Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What was ENDONOVO THERAPEUTICS, INC. (ENDV)'s cash from operating activities in fiscal 2022?
ENDONOVO THERAPEUTICS, INC. (ENDV) reported cash from operating activities of -$678,838 for fiscal 2022 (the year ended Dec 31, 2022), against -$986,584 the year before. Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What are ENDONOVO THERAPEUTICS, INC. (ENDV)'s total assets?
As of Dec 31, 2022, ENDONOVO THERAPEUTICS, INC. (ENDV) reported total assets of $1.3 million, against $2 million a year earlier (-36.2%). Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What are ENDONOVO THERAPEUTICS, INC. (ENDV)'s total liabilities?
As of Dec 31, 2022, ENDONOVO THERAPEUTICS, INC. (ENDV) reported total liabilities of $33.5 million, against $17.8 million a year earlier (+88.2%). Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What are ENDONOVO THERAPEUTICS, INC. (ENDV)'s cash and cash equivalents?
As of Dec 31, 2022, ENDONOVO THERAPEUTICS, INC. (ENDV) reported cash and cash equivalents of $98, against $85,936 a year earlier (-99.9%). Source: the 10-K filed with the SEC on Apr 17, 2023. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:ENDV&period_type=annual&limit=5"

Information only, not investment advice.